Emerging Treatment Landscape and Future Outlook for Friedreich Ataxia

Video content above is prompted by the following:

• A new drug application has been submitted for vatiquinone, an emerging 15-lipoxygenase inhibitor drug, for its treatment effects on upright stability in patients with Friedreich ataxia.
• Please discuss the targeted patient population, quality-of-life data, and safety profile for vatiquinone.
• The FDA also recently provided clearance for a first-in-industry dual route of administration of gene therapy via systemic IV infusion and direct intradentate nucleiinfusion.
• Please briefly explain the rationale of this dual-route administration.
• What are the potential implications of gene therapy, both as monotherapy and in combination with other therapies, in the treatment of Friedreich ataxia in the future?
• Please share your final thoughts on the treatment of Friedreich ataxia and the future outlook for its treatment.